Viloxazine

Structural formula
	( R ) -isomer (left) and ( S ) -isomer (right)
General
Non-proprietary name	Viloxazine
other names	( RS ) -2 - [(2-ethoxyphenoxy) methyl] morpholine; (±) -2 - [(2-ethoxyphenoxy) methyl] morpholine;
Molecular formula	C 13 H 19 NO 3
External identifiers / databases
EC number	256-281-7
ECHA InfoCard	100.051.148
PubChem	5666
ChemSpider	5464
DrugBank	DB09185
Wikidata	Q907148
Drug information
ATC code	N06 AX09
properties
Molar mass	237.29 g · mol -1
Physical state	firmly
Melting point	185–186 ° C (viloxazine hydrochloride)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Viloxazin ( Vivalan ^® ) is a selective norepinephrine reuptake inhibitor (NARI). It was developed by the pharmaceutical company AstraZeneca and launched in 1976. In July 2006 the drug was withdrawn from the market. Viloxazin was used to treat depression , and off-label for enuresis and narcolepsy .

The chemical structure of the morpholine derivative viloxazine is similar to beta blockers , but is one of the antidepressants . The racemate consists of the ( S ) - (-) - and the ( R ) - (+) - enantiomer , whereby the ( S ) - (-) - enantiomer has a five times stronger pharmacological effect.

literature

Peter Riederer, Gerd Laux, Walter Pöldinger: Neuro-psychotropic drugs. A therapy manual . Springer DE, 1993, ISBN 3-7091-6150-9 ( limited preview in Google book search).

Individual evidence

^ The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, p. 1716, ISBN 978-0-911910-00-1 .
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Peter Riederer, Gerd Laux, Walter Pöldinger: Neuro-Psychopharmaka. A therapy manual . Springer DE, 1993, ISBN 3-7091-6150-9 , pp. 403 ( limited preview in Google Book search).
↑ Danchev ND, Rozhanets VV, Zhmurenko LA, Glozman OM, Zagorevskiĭ VA: Behavioral and radio receptor analysis of viloxazine stereoisomers, Biulleten 'Eksperimental'noĭ biologii i Meditsiny 97 (5): 576-8. PMID 6326891 .

[MerckIndex-1] The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, p. 1716, ISBN 978-0-911910-00-1 .

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Peter_Riederer,_Gerd_Laux,_Walter_Pöldinger-3] Peter Riederer, Gerd Laux, Walter Pöldinger: Neuro-Psychopharmaka. A therapy manual . Springer DE, 1993, ISBN 3-7091-6150-9 , pp. 403 ( limited preview in Google Book search).

[Danchev-4] Danchev ND, Rozhanets VV, Zhmurenko LA, Glozman OM, Zagorevskiĭ VA: Behavioral and radio receptor analysis of viloxazine stereoisomers, Biulleten 'Eksperimental'noĭ biologii i Meditsiny 97 (5): 576-8. PMID 6326891 .